Pahr Therapeutics

Pahr Therapeutics, Inc.Founded in 2025, Pahr Therapeutics, Inc. specializes in creating therapies for pulmonary arterial hypertension (PAH).Pahr Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for pulmonary arterial hypertension (PAH). The firm focuses on creating novel mechanisms that target the underlying pathophysiology of PAH, aiming to offer more effective therapeutic options for patients. Their flagship products are designed to improve hemodynamics and exercise capacity in individuals suffering from this debilitating condition. Pahr Therapeutics primarily serves healthcare providers, hospitals, and specialty pharmacies within the North American and European markets, targeting both clinicians and patients who require advanced treatments for PAH.The revenue model for Pahr Therapeutics is centered around partnerships with healthcare providers and institutions involved in the treatment of PAH. Transactions typically occur through collaborations with hospitals and specialty pharmacies, which may involve research agreements or licensing arrangements for their proprietary therapies. These partnerships facilitate the distribution of their therapeutic products directly to healthcare providers, ensuring that patients have access to cutting-edge treatments. Revenue generation is bolstered by the sale of their core products, with pricing structures reflecting the specialized nature of these innovative therapies.In July 2025, Pahr Therapeutics, Inc. The company aims to expand its product offerings and enter new markets, particularly targeting regions beyond North America and Europe. Plans for upcoming product launches are set for the next few years, aligning with the company's strategy to address global healthcare needs in PAH management.

1. Seed

   Feb 27, 2025

   Amount

   $4.7M

   Investors

   Locked